Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 992 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Cancer Clear all
Active, not recruiting Not applicable Interventional

Text -Based Depression Screening Among Cancer Survivors

NCT06894849
View directory record Official record
Conditions
Cancer, Depression Secondary to Other Disease, Cancer Survivor
Interventions
Text-based depression screening, Usual care (UC)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

NCT06507748
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
AlgometRx Nociometer
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 2 Interventional

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

NCT06677190
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
Interventions
Belzutifan
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jun 11, 2026, 4:07 AM EDT
Completed No phase listed Observational

The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases

NCT00005660
View directory record Official record
Conditions
Basal Cell Carcinoma, Keratosis Palmaris et Plantaris, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1977 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated)
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
32
States / cities
Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT05799274
View directory record Official record
Conditions
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
RAD301 ([68Ga]-RAD301)
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Princeton, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003597
View directory record Official record
Conditions
Cancer
Interventions
recombinant human thrombopoietin, carboplatin, etoposide, ifosfamide, G-CSF
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jun 11, 2026, 4:07 AM EDT
Terminated Phase 1 Interventional

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

NCT02672917
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
Drug
Lead sponsor
BioNTech Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

NCT04890613
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
CX-5461
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

NCT01087333
View directory record Official record
Conditions
Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

NCT05317078
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors
Interventions
AMG 794
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California • Orange, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 11, 2026, 4:07 AM EDT
Active, not recruiting Phase 2 Interventional

Ribociclib (LEE011) Rollover Study for Continued Access

NCT02934568
View directory record Official record
Conditions
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Terminated No phase listed Observational

Ultrasound and Other Images of Artery Blockages

NCT01419574
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

NCT04589624
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Not listed Phase 1Phase 2 Interventional

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

NCT04780217
View directory record Official record
Conditions
Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer, NSCLC, Ovarian Cancer, Endometrial Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Plantation, Florida • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 11, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

ABT-751 in Treating Young Patients With Refractory Solid Tumors

NCT00036959
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ABT-751
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Chicago, Illinois • Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jun 11, 2026, 4:07 AM EDT
Suspended Phase 1 Interventional

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

NCT03065062
View directory record Official record
Conditions
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
Interventions
Palbociclib, Gedatolisib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 2 Interventional

Halt Aging in Survivors of Blood Cancers

NCT07292272
View directory record Official record
Conditions
Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
Interventions
Behavioral Coaching Intervention, Virtual Exercise Platform
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

NCT05568095
View directory record Official record
Conditions
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Interventions
Domvanalimab, Zimberelimab, Capecitabine, Fluorouracil, Leucovorin, Oxaliplatin, Nivolumab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Santa Monica, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting No phase listed Observational

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

NCT03555851
View directory record Official record
Conditions
Leukemia, Not Otherwise Specified, Leukemia, Other
Interventions
Cyclophosphamide, Specimen collection
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Recruiting Phase 2 Interventional

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Platinum-based chemotherapy, REGN7075
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
14
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 11, 2026, 4:07 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

NCT02715531
View directory record Official record
Conditions
Solid Tumor
Interventions
5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jun 11, 2026, 4:07 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

NCT01607905
View directory record Official record
Conditions
Solid Tumor
Interventions
Selinexor, Acetaminophen
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Tampa, Florida • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 11, 2026, 4:07 AM EDT
Completed Phase 3 Interventional Results available

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

NCT03465722
View directory record Official record
Conditions
GIST
Interventions
avapritinib, regorafenib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Phoenix, Arizona • Santa Monica, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jun 11, 2026, 4:07 AM EDT